The novel A2aR antagonist DZD2269 could reverse the immunosuppression induced by high concentration eAdo and play a more significant anti-tumor effect when combined with ICIs, radiotherapy, or chemotherapy (23). This evidence concerns the gene ADORA2A and neoplasm.